Cell therapy Archives

News and Trends 10 Nov 2016

UPDATE: FDA Lifts Hold on Adaptimmune’s Rare Cancer Trials

The FDA puts one of Adaptimmune‘s TCR trials on a partial hold, pending more information about the production of its cell therapy. It’s more waves for the Biotech’s financial rocking boat. Oxford-based Adaptimmune is one of the European players in TCR therapies. Besides being listed on the NASDAQ, it got GSK on board on a €311M […]

November 10, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 10 Nov 2016

European Biotech is working hard to Beat back Melanoma

Immunocore and Pierre Fabre have been representing Europe in this years’ Society for Melanoma Research Congress. This type of cancer may have its days counted! This week, scientists from around the globe met at the MRC to get an update on what’s going on in the fights against melanoma, the least common but most deadly skin […]

November 10, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Oct 2016

TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer

Adaptimmune and MSD are collaborating to test a therapy for multiple myeloma that combines some of the most promising technologies in immuno-oncology: TCR and checkpoint inhibitors. Adaptimmune is an immuno-oncology billion-euro Biotech from the British Golden Triangle. Despite some trouble with the FDA recently, the company continues to forge ahead with its promising TCR technology. Now, […]

October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2016

This Technology Opens new Horizons for Protein Production

Based in Cologne, Germany, Cevec focuses on human cell-based expression system for production of biological therapies. We’ve already covered their breakthroughs for safer gene therapy and the potential of CAP-GT for expression of viral vectors. Besides CAP-GT, CEVEC has also developed a cell line that can produce complex glycosylated proteins. A good example of glycosylated protein is […]

October 19, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 13 Oct 2016

Adaptimmune Revises TCR Protocol following Phase I/IIa Failure

Shares of Adaptimmune slid 12% yesterday morning after the company updated its TCR therapy to include fludarabine, which was linked to deaths in Juno’s CAR-T trials. Despite optimism that T-cells are the key to cancer cures, the field has taken a number of hits this year. Most recently, the FDA put a partial hold on […]

October 13, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 29 Sep 2016

Titans in Gene Therapy and TCRs make a Massive Deal

Medigene has licensed a few candidates from its TCR platform to one of the Boston ‘it’ biotechs in a deal totaling around €1B. By partnering with bluebird bio, Medigene is reestablishing itself as a leader in immuno-oncology. Founded over 20 years ago, Medigene has risen to the top of the European biotech scene with a […]

September 29, 2016 - 3 minutesmins - By Evelyn Warner

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cell therapy

UPDATE: FDA Lifts Hold on Adaptimmune’s Rare Cancer Trials

European Biotech is working hard to Beat back Melanoma

TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer

This Technology Opens new Horizons for Protein Production

Adaptimmune Revises TCR Protocol following Phase I/IIa Failure

Titans in Gene Therapy and TCRs make a Massive Deal

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!